✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹843 Cr.
P/E
29.02
About
Shree Ganesh Remedies is engaged in manufacturing and dispatch of drug intermediates and chemicals like amine hydrochloride and specialty fine chemicals for pharmaceutical industry. The company manufa… Read more
Shree Ganesh Remedies is engaged in manufacturing and dispatch of drug intermediates and chemi… Read more
Low
558
52W Range
High
950
  • Shree Ganesh Remed.
  • NGL Fine-Chem
  • AMI Organics

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Custom financial statementNew
Edit rows
Forensics

10 Yes

Positive for this company

2 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

Revenue mix

Location Wise Break-Up

Segment Wise Break-Up

Operational Metrics

R&D as a % of Total Sales (%)

  • Shree Ganesh Remedies Ltd.
Select a Metric
  • R&D as a % of Total Sales (%)
Peer Comparison
FAQs on Shree Ganesh Remedies Ltd. Business

Shree Ganesh Remedies produces and supplies drug intermediates and specialty chemicals for the pharmaceutical industry. Their product range includes items related to antipsychotic, antiseptic, deprotonation reactions, hyperlipidemia, alzheimers, and anti-viral drugs.

Shree Ganesh Remed. major competitors are NGL Fine-Chem, AMI Organics, Kopran, Hester Biosciences, Nectar Lifesciences, Themis Medicare, SMS Lifesciences.
Market Cap of Shree Ganesh Remed. is ₹869 Crs.
While the median market cap of its peers are ₹764 Crs.

Shree Ganesh Remed. seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing
2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Investor Presentation Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Mar Mar Jun Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Discussions & Analysis
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material